3月3日,跨国药企艾伯维与丹麦公司Gubra宣布达成一项许可协议,共同开发GUB014295,这是一种潜在治疗肥胖症的同类最佳长效胰淀素(amylin)类似物。艾伯维首席执行官Robert A. Michael称,与 Gubra 的合作标志着艾伯维进入肥胖症领域。根据协议条款,艾伯维将在全球范围内领导GUB014295的开发和商业化活动。Gubra将获得总额为3.5亿美元的预付款,并有资格获得高达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.